Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTR-II: Reprieve System in Acute Decompensated Heart Failure
NCT06898515Phase 3Recruiting
- Sponsor
- Reprieve Cardiovascular
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in heart failure (HF) (3 arms), sponsored by Reprieve Cardiovascular. Primary endpoints: Hierarchical composite/win-ratio and Incidence of device/procedure-related adverse events. Started Jul 2025; status: recruiting.
02
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06898515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898515.